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CCN3 is a matricellular protein that promotes oligodendrocyte pro-
genitor cell differentiation and myelination in vitro and ex vivo. CCN3
is therefore a candidate of interest in central nervous system (CNS)
myelination and remyelination, and we sought to investigate the
expression and role of CCN3 during these processes. We found CCN3
to be expressed predominantly by neurons in distinct areas of the CNS,
primarily the cerebral cortex, hippocampus, amygdala, suprachiasmatic
nuclei, anterior olfactory nuclei, and spinal cord graymatter. CCN3was
transiently up-regulated following demyelination in the brain of
cuprizone-fed mice and spinal cord lesions of mice injected with lyso-
lecithin. However, CCN3−/− mice did not exhibit significantly different
numbers of oligodendroglia or differentiated oligodendrocytes in the
healthy or remyelinating CNS, compared to WT controls. These results
suggest that despite robust and dynamic expression in the CNS, CCN3
is not required for efficient myelination or remyelination in the murine
CNS in vivo.
CCN3 | myelin | oligodendrocyte | OPC | remyelination
Myelin is a lipid-rich, lamellar structure that ensheaths axonsin the peripheral and central nervous systems (CNS). In
the CNS, these sheaths are formed by differentiated oligoden-
drocytes. Myelin enables saltatory conduction of action potentials
along axons (1, 2), provides axonal metabolic support via metab-
olite delivery (3, 4) and is required for efficient motor skill
learning (5, 6). When myelin is damaged in pathologies such as
multiple sclerosis (MS), substantial neurological function deficits
can arise. There are currently no therapies targeting myelin re-
generation, but proof-of-concept studies and clinical trials have
shown that enhancing remyelination can improve neurological
function (7, 8). These reports show value in studying mechanisms
that may regulate oligodendrocyte progenitor cell (OPC)
differentiation and remyelination.
Recently, we reported that regulatory T cells (Treg) were nec-
essary for efficient murine CNS remyelination (9). We also
showed that Treg secrete cellular communication network factor 3
(CCN3) and that Treg-derived CCN3 enhances OPC differentia-
tion and myelination in mixed glial and brain slice cultures, re-
spectively (9). CCN3, previously known as nephroblastoma
overexpressed (NOV) (10, 11), is a matricellular protein of the
CCN family (comprising CCN1-6). CCN3 was discovered as a
gene overexpressed in myeloblastosis associated virus (MAV)-in-
duced nephroblastomas in chickens (10), and this study first
reported that CCN3 is highly expressed throughout development
in the brain of chickens. CCN3 has since been shown to be present
in neurons in distinct areas of the rat brain (12), human fetal and
adult brain, spinal cord, and in cerebrospinal fluid (13, 14). CCN3
is also expressed by primary rat astrocytes in vitro (15, 16), rat
cerebral cortex astrocytes in vivo, and regulates astrocytic ex-
pression of CCL2 and CXCL1 chemokines in vitro (16). In rat
brain, CCN3 was detected in Purkinje neurons and negatively
regulated granule neuron precursor proliferation during cerebellar
development (17). Low levels of CCN3 mRNA and protein were
detected at murine embryonic development day 15 (E15) and
gradually increased until postnatal day 21 (P21) (18). Interestingly,
overexpressing CCN3 in mouse cerebral cortex at E14 inhibited
callosal projections during development (18). These reports suggest
that CCN3 plays a role in murine CNS development, but, in gen-
eral, functions of CCN3 in the CNS remain poorly characterized.
Interestingly, neuronal- and Schwann cell-derived CCN2 in-
hibits OPC differentiation and myelination (19–21). In a model
of amyotrophic lateral sclerosis, treating mice with CCN2-
neutralizing antibodies decreased sciatic nerve myelin de-
generation (22). CCN2 and CCN3 can mutually regulate each
other as shown in chondrocyte, glomerular cell, and fibrotic
disease studies (23–26) where they exhibited reciprocal nega-
tive regulation. Therefore, CCN2 and CCN3 may be a regula-
tory duo in OPC differentiation and myelination, providing
further rationale for our central hypothesis that CCN3 supports
(re)myelination in vivo.
Whether CCN3 is indeed required for efficient CNS (re)
myelination remains to be determined. Furthermore, whereas
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ccn3 mRNA expression in the murine CNS can be investigated
in silico using in situ hybridization (ISH) and RNA sequencing
(RNAseq) database resources (27–29), CCN3 protein expression
in distinct anatomical regions has not been investigated. We
sought to address these questions of CCN3 in myelin develop-
ment and regeneration as well as provide a characterization of
CCN3 expression in the adult murine CNS that will serve as a
framework for future investigations of roles of CCN3 in the CNS.
Results
CCN3 Is Expressed by Neurons in Distinct Anatomical Regions of the
Murine CNS. Ccn3 mRNA expression in the murine brain can be
investigated in databases generated using ISH and RNAseq tech-
nologies (27–29). However, the presence of mRNA transcripts
within a sample does not necessarily report the presence of corre-
sponding protein counterparts (30, 31) and vice versa. Importantly,
in many of these applications, tissue architecture is lost during
processing. This is a significant limitation, particularly in the brain,
which comprises many nuclei and anatomical regions, each involved
in distinct neurological functions. Elucidating what cells express a
protein of interest, but also where in the CNS such proteins are
expressed, may help uncover CCN3 physiological functions. Fur-
thermore, for CCN proteins (CCN2 and CCN3) there is evidence
showing that in different biological systems there is no strict match
between the level of CCN proteins and corresponding RNA species
in various human tissues (26, 32, 33). Therefore, we sought to
characterize CCN3 protein expression in the adult murine CNS
using immunohistochemistry.
First, we validated the specificity of anti-CCN3 antibody using
brain tissue from WT (SI Appendix, Fig. S1A) and CCN3−/− (SI
Appendix, Fig. S1B) mice and included isotype and secondary-only
antibody controls (SI Appendix, Fig. S1 C and D). Immunohisto-
chemical studies identified that CCN3 was expressed primarily by
NeuN+ neurons in distinct CNS areas. A prominent site of CCN3
expression was the hippocampus, particularly the CA1 field and
subiculum (Fig. 1 A–C). Interestingly, a murine cortex and hip-
pocampal single-cell (sc) RNAseq database designates ccn3 as a
layer-specific marker of the hippocampal CA1 field (28). Likewise,
using a murine scRNAseq resource (29), we found ccn3 is the
most enriched gene in excitatory neurons of the CA1 field. CCN3
was also highly expressed in the cerebral cortex, especially in layers
2/3 and 5 (Fig. 1 D–F) and piriform cortex (Fig. 1G). CCN3 ex-
pression was detected in every cerebral cortex anatomical region
investigated (SI Appendix, Fig. S2 A and B).
Intriguingly, CCN3 appeared to be present extracellularly in the
suprachiasmatic nuclei (SCN), suggesting CCN3 may play a role in
circadian biology (Fig. 1H). Some CCN3+ cells were present in the
ventrolateral SCN (Fig. 1H), many of which did not colocalize
with NeuN. CCN3 was also detected in the anterior olfactory
nuclei (AON) (Fig. 1I), which, together with CCN3 expression in
the piriform cortex, suggests that CCN3 may play a role in ol-
faction. Finally, CCN3 was detected in the basomedial amygdala
nuclei (Fig. 1J and SI Appendix, Fig. S2 A and B). In the thoracic
spinal cord, CCN3 was detected exclusively in a few neurons of the
central canal (Fig. 1K). CCN3 immunoreactivity was not detected
in cerebellum (Fig. 1L), contrary to a murine ISH database
showing that ccn3 is expressed in the Purkinje cell layer (27). Fi-
nally, CCN3 was detected in the eye in Bruch’s membrane
(Fig. 1M), suggesting a potential role in oxygen, nutrient, or waste
exchange regulation between circulation and the retina. Taken
together, these results suggest that based on localization, CCN3
may have diverse roles in the CNS such as neuronal homeostasis
or synaptic activity modulation in behavior, emotion, memory
consolidation, and circadian regulation.
CCN3 Is Not Required for Myelination Ex Vivo. We have previously
shown that exogenous Treg-derived CCN3 enhances myelination
ex vivo (9). Here, we have detected that murine neonatal
cerebellar/brainstem slices initially secrete CCN3. However,
CCN3 becomes undetectable by day 9 (Fig. 2A). To investigate the
cellular source of CCN3 expression in this model, WT cerebellar/
brainstem slices were cultured for 2 and 4 d and immunohisto-
chemistry was performed. Few CCN3+ cells were detected, and
most of these cells were NeuN+ neurons (SI Appendix, Fig.
S3 B–F). Whereas most of the CCN3+ cells were found in clusters
within the brainstem, individual isolated CCN3+ cells were also
observed (SI Appendix, Fig. S3 B and C). There was no significant
difference in the number of CCN3+ or CCN3+NeuN+ cells in
slices cultured for 2 or 4 d (SI Appendix, Fig. S3 D–F). CCN3
immunoreactivity did not colocalize with amyloid precursor pro-
tein (APP) (SI Appendix, Fig. S3A). Furthermore, the morphology
of APP immunoreactivity in this tissue remained mostly cellular as
opposed to bulbar.
To determine if brain slice-derived CCN3 was necessary for
myelination, cerebellar/brainstem slices from WT and CCN3−/−
mice were cultured for up to 14 d. These slices contain resident
OPCs that differentiate into myelin-producing oligodendrocytes and
myelinate axons ex vivo (34). There was no difference in myelina-
tion indices between groups (MBP+NFH+ colocalization area/
NFH+ total area) after 7 or 14 d ex vivo, suggesting CCN3 was not
required for CNS myelination in this model (Fig. 2 B–E). Despite
the relevance of this model, it has caveats. Brain slices are discon-
nected from vasculature and, therefore, from peripheral immune
cells that may influence oligodendrogenesis and myelination (35)
and also lack spatial and temporal regulation of myelination (36).
For these reasons, as well as our findings that CCN3 is extensively
expressed in the murine CNS, we sought to determine whether
CCN3 was required for CNS myelination in vivo.
CCN3 Is Not Required for Oligodendrocyte Development and Myelination
In Vivo. To investigate if CCN3 is required for myelination in vivo,
oligodendrocyte differentiation was first investigated in spinal cord
and brain of healthy adult WT and CCN3−/− mice. There was no
significant difference in the density of Olig2+ oligodendrocyte
lineage cells (OLCs) or Olig2+CC1+ differentiated oligodendro-
cytes between groups in spinal cord ventral white matter (vWM)
(Fig. 3 A–C) or the corpus callosum (Fig. 3 D–F), suggesting that
CCN3 is not required for oligodendrocyte development in vivo. As
OLCs exhibit different morphology, proliferative capacity, and
density in diverse white and gray matter (GM) regions (37), we
asked whether these results were reproducible in GM. There was
also no significant difference in densities of Olig2+ OLCs and
Olig2+CC1+ oligodendrocytes between groups in the medial motor
cortex (Fig. 3 G–I). Staining of myelin in CCN3−/− brain tissue
showed no qualitative gross deficiency in the corpus callosum or
cerebral cortex (Fig. 3 J and K), suggesting CCN3 deficiency does
not overtly impact CNS myelination. However, this approach does
not show if myelin wrapping is impaired in the absence of CCN3.
Therefore, semithin spinal cord sections from WT and CCN3−/−
mice were stained with toluidine blue and numbers of myelinated
axons quantified in vWM. There was no significant difference in
numbers of myelinated axons between groups (Fig. 3 L and M),
providing further evidence that CCN3 is not required for myelina-
tion in vivo. To ensure these findings were not skewed by a dif-
ference in axon numbers between genotypes, NFH+ axons were
quantified in vWM of WT and CCN3−/− mice and no significant
difference was observed (Fig. 3 N and O). Together, these results
indicate that CCN3 is not essential for oligodendrocyte develop-
ment or myelination in vivo.
CCN3 Is Up-Regulated in Spinal Cord White Matter during Remyelination.
CCN expression is dynamically regulated in response to stress, in-
flammation, injury, and repair (38). To determine if CCN3 was
differentially expressed during CNS remyelination, CCN3+ cells
were quantified in demyelinating and remyelinating spinal cord le-
sions induced by administration of lysolecithin, at 5 and 14 d














































postlesioning (dpl). CCN3 expression was significantly up-regulated
in lesions at 5 dpl compared to untreated controls and was still
detectable at 14 dpl but at lower levels. These results suggest dy-
namic regulation of CCN3 expression following myelin damage and
during regeneration (Fig. 4 A–C). Interestingly, ∼65% of CCN3-
expressing cells were Olig2+ at the peak of expression (Fig. 4 D and
E), showing that cells of the oligodendrocyte lineage express CCN3.























































Fig. 1. CCN3 is expressed in anatomically distinct regions of the healthy adult murine CNS. Representative images of CCN3 and NeuN staining in CA1 field of
hippocampus (A and B), subiculum (A and C), cerebral cortex (D–F), piriform cortex (G), suprachiasmatic nuclei (H), anterior olfactory nuclei (I), basomedial
amygdala nuclei (J), thoracic spinal cord (K), cerebellum (L), and retina (M). (Scale bars: 100 μm [A; D; G; H; I, b; J; and K, a], 50 μm [M], 25 μm [B; C; E; F; I, c; and
K, b], and 0.5 mm [I, a and L].) AON, anterior olfactory nuclei; BMA, basomedial amygdala nuclei; BrM, Bruch’s membrane; CA1, subfield 1 of hippocampus;
CB, cerebellum; cc, corpus callosum; GM, gray matter; L, layer; MOB, main olfactory bulb; Pir, piriform cortex; SCN, suprachiasmatic nuclei; SUB, subiculum;
WM, white matter.







































expressed by OPCs or differentiated oligodendrocytes in this model.
Whereas most CCN3+Olig2+ cells were CC1−, a small number of
cells were CCN3+Olig2+CC1+ differentiated oligodendrocytes
(Fig. 4 F, G, I, and J). It is worth noting that only ∼6% of Olig2+
OLCs expressed CCN3 at 5 dpl, and this proportion decreased to
∼1% by 14 dpl (Fig. 4H). We found that CCN3 was also expressed
by GFAP+ glia within these lesions (Fig. 4 K–N), which could be
astrocytes or potentially Schwann cells (39), and that these cells
constituted ∼55% of CCN3+ cells at 5 dpl (Fig. 4O). These results
demonstrate that CCN3 is transiently up-regulated during spinal
cord remyelination, suggest that both Olig2+ and GFAP+ glia ex-
press CCN3 during this process, and that there may be a small
population of CCN3+ glia expressing both Olig2 and GFAP.
CCN3 Is Up-Regulated in the Lateral Septum and Corpus Callosum during
Demyelination and Concomitant Remyelination.To investigate if CCN3
was differentially expressed during brain demyelination/remyelina-
tion, WT mice were fed 0.2% cuprizone to induce demyelination
and then changed to regular chow to allow remyelination to occur.
Demyelination was confirmed by MBP, degraded MBP (dMBP)
and Iba1 staining showing microglia/macrophage infiltration in the
corpus callosum, the largest white matter tract in the brain and a
consistent area of demyelination in this model (40) (SI Appendix,
Fig. S1 G and H). CCN3 was detected in the corpus callosum 4 wk
after cuprizone-induced demyelination (Fig. 5 B, D, and E). Fur-
thermore, CCN3 was detected in the lateral septum after 3, 4, and 5
wk of demyelination and expression peaked at 4 wk (Fig. 5 A and
C). To identify the source of CCN3 expression in this model, tis-
sues were costained with cell or axonal-specific markers. CCN3
partially colocalized with NF200+ axons (Fig. 5E). Interestingly,
the CCN3 immunoreactivity pattern in this tissue closely re-
sembled that of axonal ovoids, pathologic structures which occur
as a result of axonal stress, transection, or degeneration (41) and
previously described during cuprizone-induced demyelination (42,
43). Moreover, CCN3 immunoreactivity partially colocalized with
APP, which is expressed in neurons and accumulates in transected
axons as a result of interrupted anterograde transport (44)
(Fig. 5E). CCN3 did not colocalize with Olig2 in the corpus cal-
losum (Fig. 5D), demonstrating differences in cellular sources in
different models of demyelination/remyelination. This may be due
to anatomical differences (spinal cord vs. brain) or the kinetics of
demyelination/remyelination caused by different toxins and



























































Fig. 2. CCN3 is not required for myelination ex vivo. (A) CCN3 protein quantification via ELISA in cerebellar/brainstem slice conditioned media. Data are
mean ± SD. Representative confocal projection images of MBP and NFH staining in brain slices at 7 (B) and 14 days ex vivo (dev) (D). (Scale bars: 25 μm.)
Myelination index quantification (MBP+NFH+ colocalization area/NFH+ total area) of brain slices at 7 (C) and 14 dev (E). Data are mean ± SEM. ns, not sig-
nificant. Statistical analysis: Mann–Whitney U test (C) or unpaired, two-tailed, Student’s t test (E). n = 3 wells containing 3 slices each (A) and 4–5 animals per
group (C and E).














































emphasizes the importance of comprehensive investigation of
CNS remyelination. CCN3 up-regulation during CNS demyelination/
remyelination led us to further investigate whether CCN3 deficiency
impairs OPC differentiation during CNS remyelination.
CCN3 Is Not Required for Efficient OPC Proliferation or Differentiation
during CNS Remyelination. To examine the role of CCN3 in OPC
proliferation and differentiation during myelin regeneration,
demyelination was induced by lysolecithin injection in the tho-
racic vWM of WT and CCN3−/− mice. Demyelination was con-
firmed by MBP and Iba1 staining at 5 dpl and Black Gold II
staining at 14 dpl (Fig. 6 A, B, and H). There was no significant
difference in densities of Olig2+ OLCs in lesions at 5 or 14 dpl
(Fig. 6 E and K), Olig2+Ki67+ proliferating OPCs at 5 dpl
(Fig. 6 C, D, and F), or Olig2+CC1+ oligodendrocytes at 14 dpl






























































































































































































Fig. 3. CCN3 is not required for CNS myelination in vivo. Representative images of Olig2 and CC1 staining in spinal cord vWM (A), medial corpus callosum (D),
and motor cortex (G). OLC (B) and differentiated oligodendrocyte quantification (C) in spinal cord vWM. OLC (E) and differentiated oligodendrocyte
quantification (F) in the medial corpus callosum. OLC (H) and differentiated oligodendrocyte quantification (I) in motor cortex. Representative images of
Black Gold II myelin staining in medial corpus callosum (J) and motor cortex (K). (L) Representative images of toluidine blue staining of semithin spinal cord
vWM sections. (M) Myelinated axon quantification in spinal cord vWM. (N) Representative images of NFH staining in spinal cord vWM. (O) Axonal quanti-
fication in spinal cord vWM. (Scale bars: 100 μm [A, a; J; and K], 50 μm [G, a and D], and 25 μm [A, b; G, b; L; and N].) Data are mean ± SEM. ns, not significant.
Statistical analysis: (B, C, E, F, H, I, M, O) unpaired, two-tailed, Student’s t tests. n = 4–6 (B, C, E, F, H, I, and O) and 3 (M) animals per group.
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Fig. 4. CCN3 is transiently up-regulated in the spinal cord during remyelination. Representative images of CCN3 and Olig2 (A), CCN3, Olig2 and CC1 (F), and
CCN3 and GFAP (K) staining in spinal cord of untreated controls, and 5 and 14 dpl after lysolecithin injection. (B) Representative confocal images of CCN3 and
Olig2 staining in spinal cord lesions at 5 dpl. White arrowheads, CCN3+Olig2− cells; yellow arrowheads, CCN3+Olig2+ cells. CCN3+ cells (C), CCN3+Olig2+ cells
(D), and percentage of CCN3+Olig2+ cells (E) quantification in untreated, 5 dpl, and 14 dpl spinal cord vWM. (G) Representative images of CCN3, Olig2, and
CC1 staining in spinal cord lesions at 5 dpl. Yellow arrowheads, CCN3+Olig2+CC1+ cell. Proportion of OLCs that are CCN3+ (H), CCN3+Olig2+CC1+ cells (I) and
proportion of CCN3-expressing OLCs that are CC1+ (J) quantification in untreated, 5 dpl, and 14 dpl spinal cord vWM. (L) Representative confocal images of
CCN3 and GFAP staining in spinal cord lesions at 5 dpl. White arrowheads, CCN3+GFAP− cells; yellow arrowheads, CCN3+GFAP+ cells. CCN3+ cells (M),
CCN3+GFAP+ cells (N), and percentage of CCN3+GFAP+ cell quantification (O) in untreated, 5 dpl, and 14 dpl spinal cord vWM. (Scale bars: F and K, 100 μm; A,
50 μm; B, G, and L, 25 μm.) Data are mean ± SEM. ns, not significant; *P < 0.05; **P < 0.01. Statistical analysis: Kruskal–Wallis with Dunn’s Multiple Comparison
test. n = 4–10 animals per group.














































percentages of proliferating (Fig. 6G) or differentiated (Fig. 6M)
OPCs at 5 and 14 dpl, respectively.
To validate these results in the brain and a different model of
toxin-induced demyelination, WT and CCN3−/− mice were fed
cuprizone to induce demyelination as described earlier and oli-
godendrocyte differentiation was quantified in the corpus cal-
losum. Demyelination was confirmed by Black Gold II staining
(Fig. 7A). There was no significant difference in the density of
Olig2+ oligodendroglia and Olig2+CC1+ oligodendrocytes be-
tween groups (Fig. 7 B–D), suggesting that CCN3 is not required
for OPC differentiation during remyelination in the CNS.
Discussion
In this study, we provide a comprehensive characterization of
CCN3 protein expression in the adult, healthy murine CNS.
Using immunohistochemistry, we showed that CCN3 is expressed
predominantly by NeuN+ neurons in specific anatomical regions
of the brain and spinal cord. CCN3 was not detected in the retina
or optic nerve but was detected in Bruch’s membrane. Further-
more, we show that CCN3 was transiently up-regulated during
CNS demyelination and remyelination but is not necessary for
efficient OPC differentiation during myelin regeneration. Like-
wise, healthy CCN3−/− mice do not exhibit overt abnormalities in
CNS OLC density or myelination. These in vivo studies are
somewhat in contrast with our earlier report showing that (i) ex-
ogenous CCN3 purified from Treg cultures enhanced brain slice
myelination ex vivo and (ii) depletion of CCN3 from Treg-
conditioned media abrogated OPC differentiation and myelina-
tion driven by Treg-conditioned media (9). Interestingly, in pure
OPC cultures, we observed that Treg-derived CCN3 did not drive
OPC differentiation (SI Appendix, Fig. S4 A and B). This suggests
the previously reported (9) positive effect of CCN3 on OPC dif-
ferentiation in mixed glial cultures may have been indirect and
potentially involved other CNS cell types such as astrocytes, neu-
rons, microglia, pericytes, or even small populations of endothelial
cells found within this model (45). Our findings highlight the
complexity of CCN biology. Although we showed that CCN3 is
expressed primarily by NeuN+ neurons in distinct areas of the
mouse CNS, we have also shown that Olig2+, Olig2+CC1+, and
GFAP+ glia express CCN3 during spinal cord remyelination. In-
terestingly, around 65% or 55% of CCN3+ cells in this model
expressed Olig2 or GFAP, respectively. This discrepancy might be
due to a small percentage of astrocytes and/or Schwann cells
reported to arise from oligodendrocyte precursors in the remyeli-
nating spinal cord (39, 46). Alternatively, this overlap may be due to
slight variations in cell counting and/or examination of different
tissue sections from the same experiment.
Regardless of the requirement (or lack thereof) of CCN3 in
myelination and myelin regeneration, our CCN3 expression
studies in healthy murine CNS show that CCN3 is expressed
predominantly by neurons in distinct CNS regions. The brain
nuclei specificity of expression suggests CCN3 may be involved in
distinct functional neurological roles such as olfaction, circadian
rhythm, or memory consolidation among others. Behavioral,
motor function, learning and memory, stress response, and visual
functional studies as well as identifying which types of neurons
express CCN3 may reveal novel functions in the CNS. Impor-
tantly, our finding that CCN3 is up-regulated after CNS injury
(demyelination in this case) and that it is detected in axonal
ovoids characteristic of degenerating axons in the brain suggests
CCN3 may be involved in neurodegeneration, opening an in-
teresting avenue of research. An alternative explanation is that
CCN3 may be produced by neurons and move along axons via
axoplasmic anterograde transport, as previously suggested in
ISH and immunohistochemical studies in the kidney (32). When
this transport is blocked due to axonal stress or transection,
CCN3 may then accumulate in axonal ovoids and become de-
tectable. Furthermore, since CCN3 appears to be up-regulated in
injury and regenerative settings, it is possible that our findings
showing CCN3 detection in neurons of cerebellar/brainstem slice
A B C
D E
Fig. 5. CCN3 is transiently up-regulated in the lateral septum and corpus callosum during demyelination. (A) Representative images of CCN3 staining in
septal nuclei and corpus callosum in untreated controls, cuprizone-induced demyelination, and remyelination. cc, corpus callosum; ls, lateral septum; lv, lateral
ventricle. (B) Representative images of CCN3 staining in the corpus callosum and lateral septum 4 wk after cuprizone-induced demyelination. (C) Percentage
of CCN3+ area quantification in septal nuclei of untreated, cuprizone-fed and cuprizone-withdrawn mice. (D) Representative confocal images of CCN3, Olig2,
and CC1 staining in the medial corpus callosum of untreated controls and WT mice fed with cuprizone for 4 wk. (E) Representative confocal images of CCN3,
NF200, and APP staining in the lateral septum and corpus callosum 4 wk after cuprizone-induced demyelination. (Scale bars: A, 200 μm; B, 50 μm; D and E, 25
μm; E, a and b, 10 μm.) Data are mean ± SEM. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001. Statistical analysis: Kruskal–Wallis with Dunn’s Multiple
Comparison test. n = 4–6 animals per group.
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Fig. 6. CCN3 is not required for OPC proliferation or differentiation during spinal cord remyelination. Representative images of Iba1 and MBP (A and B) and
Olig2 and Ki67 (C and D) staining 5 dpl after lysolecithin injection in spinal cord vWM. White arrowheads, Olig2+Ki67+ cells. OLC (E), proliferating OPC (F), and
percentage of proliferating OPC quantification (G) at 5 dpl. Representative images of Black Gold II (H) and Olig2 and CC1 (I and J) staining at 14 dpl. White
arrowheads, Olig2+CC1+ cells. OLC (K), differentiated oligodendrocyte (L), and percentage of differentiated OPC quantification (M) at 14 dpl. (Scale bars: A, C,
and I, 100 μm; H, 50 μm; B, D, and J, 25 μm.) Data are mean ± SEM. ns, not significant. Statistical analysis: unpaired, two-tailed, Student’s t tests (E, F, K, and L)
or Mann–Whitney U tests (G and M). n = 4–5 (E–G) and 11 (K–M) animals per group.














































cultures and associated conditioned media were a result of tissue
slicing during culture preparation. However, it remains a possi-
bility that this differential expression pattern occurs as a result of
developmental regulation, as opposed to injury. In summary,
CCN3 is not crucial for efficient myelination or OPC differen-
tiation during myelin regeneration in the range of murine ex-
perimental models tested, but likely plays key roles in the CNS in
health and disease. These topics warrant further investigation
and the studies described here lay a foundation for such studies.
Materials and Methods
Animals. All mice used in this study were on a C57BL/6 background and bred in-
house or purchased directly from Charles River Laboratories. Mice were
housed under standard laboratory conditions: 12/12 h light/dark cycle at 21 °C
and food available ad libitum. All experiments with CCN3−/− mice (47), used
either WT littermate controls or WT mice derived from a common original
breeding line with CCN3−/− mice. All animal maintenance and experiments
were in compliance with the UK Home Office regulations and approved by
Queen’s University Belfast Animal Welfare Ethical Review Board.
Lysolecithin-Induced Demyelination. Male mice between 8 and 10 wk of age
were used. L-α-lysophosphatidylcholine (also known as lysolecithin) from egg
yolk (Sigma) was injected in the spinal cord of mice to induce a focal
demyelinated lesion as previously described (48). Briefly, 1.2 μL of a 1% (wt/
vol) lysolecithin solution dissolved in phosphate buffered saline (PBS) (pH 7.4)
was injected into the vWM of the thoracic spinal cord between vertebrae T12
and T13. At indicated timepoints, mice were terminally anesthetized with
sodium pentobarbital and perfused transcardially with PBS followed by 4%
paraformaldehyde (PFA). Spinal cords were removed, incubated overnight in
4% PFA, and cryoprotected in 30% sucrose. Spinal cords were embedded in
OCT compound (Tissue Tek) and snap-frozen using 2-methylbutane (Honey-
well) and dry ice. Transverse, 12-μm-thick sections were cut using a Leica
cryostat. Nonconsecutive sections were collected and stained immunohis-
tochemically for various antigens. Fluorescence and brightfield images were
acquired on a Leica DM5500. Some representative images were acquired using
a Leica TCS SP8 confocal microscope. Cell numbers were counted by a blinded
observer in functional experiments comparing WT and CCN3−/− genotypes in
images of three sections per animal, and values were averaged to yield one
value per animal for statistical analysis.
Cuprizone-Induced Demyelination. Male mice between 10 and 15 wk of age
were fed 0.2% cuprizone (bis(cyclohexanone) oxaldihydrazone) (Envigo
CustomDiet, TD. 140804) or normal rodent chow for untreated controls. Food
and water were available ad libitum. Cuprizone feeding was maintained for
up to 6 wk to induce demyelination. Where indicated, diet was then changed
to normal rodent chow for an additional 2 wk to allow remyelination to
occur. At indicated timepoints, mice were terminally anesthetized with
sodium pentobarbital and perfused transcardially with PBS followed by cold
4% PFA. Brains were dissected, incubated overnight in 4% PFA, and cry-
oprotected in 30% sucrose. Brains were snap-frozen using 2-methylbutane
(Honeywell) and dry ice, and coronal frozen sections of 20 μm thickness were
cut using a Leica cryostat. Nonconsecutive sections between 1 mm
and −1 mm relative to bregma were collected and stained immunohis-
tochemically for various antigens. Fluorescence images were acquired on a
Leica DM5500 microscope, and brightfield images were acquired on a Nikon
Eclipse 80i microscope. Some representative images were acquired using a
Leica TCS SP8 confocal microscope. OLC numbers were counted in the medial
corpus callosum by a blinded observer in images of three to four sections per
animal as above. Percentage of CCN3+ area was analyzed by applying a
threshold in ImageJ and measuring the proportion of a delimited area with
values above this threshold.
Toluidine Blue Staining. Male mice between 10 and 13 wk of age were per-
fusedwith 3%glutaraldehyde and 2%PFA in 0.1Mphosphate buffer (pH 7.4)
with 0.7% (wt/vol) NaCl, and spinal cords were dissected and postfixed
overnight. Specimens were rinsed in 0.1M cacodylate, postfixed in 1% os-
mium tetroxide (Agar Scientific), dehydrated, and embedded in Durcupan
resin (Sigma). Semithin sections (750 nm) were cut on a Leica UCT ultrami-
crotome using a Histo knife (Diatome) and mounted on microscope slides.
Semithin sections were incubated in a 1% toluidine blue solution for 43 s at
60 °C and rinsed with water. Brightfield images of healthy vWM tissue de-
rived from lesioned spinal cords were acquired on a Leica DM5500 micro-
scope. The number of myelinated axons were counted by a blinded observer
on three to four sections per animal as above.
Black Gold II Myelin Staining. Frozen brain and spinal cord sections were
stained with Black Gold II (BGII) (AG105, Millipore) according to manufac-
turer’s instructions. In brief, sections were washed in water, immersed in BGII
solution at 60 °C, and incubated for 20 min, followed by incubation in 1%
sodium thiosulfate at 60 °C for 5 min. Slides were rinsed in water, dehy-
drated, incubated in Clearene (Leica) for 2 min, and coverslipped using DPX
mounting media (Sigma). Images of brain and spinal cord sections were
acquired using DM5500 and Nikon Eclipse 80i microscopes.
Immunofluorescence Staining of CNS Tissue. Frozen sections were blocked
with 10% normal donkey (Sigma) or goat serum (NGS) (Vector Laboratories)
and incubated with primary antibodies for various antigens (SI Appendix,
Table S1) overnight at 4 °C. When staining with primary antibodies against
murine CCN3, an isotype control (catalog no. I-5000, Vector Laboratories)
was used at the same final concentration. Tissue sections were then treated
with secondary antibodies and incubated for 1 h at room temperature (RT)
(SI Appendix, Table S1). For CC1 and Ki67 staining, antigen retrieval using
10% citrate buffer (Sigma) was performed. A mouse-on-mouse detection kit
was used before CC1 and NF200 staining (Vector Laboratories). Cell nuclei
















































































































Fig. 7. CCN3 is not required for OPC differentiation during remyelination in the brain. (A) Representative images of Black Gold II myelin staining in medial
corpus callosum of untreated, 6 wk demyelinated and 2 wk remyelinating WT and CCN3−/− mice. (B) Representative images of Olig2 and CC1 staining in
corpus callosum of untreated, demyelinated and remyelinating mice. (Scale bars: 100 μm.) OLC (C) and differentiated OPC quantification (D) in medial corpus
callosum. Data are mean ± SEM. ns, not significant. Statistical analysis: (C and D) Kruskal–Wallis with Dunn’s Multiple Comparison test. n = 3–6 animals
per group.







































(Thermo Fisher Scientific) before coverslipping with ProLong Gold Antifade
(Life Technologies). Images of brain and spinal cord sections were acquired
on Leica DM5500, TCS SP5 confocal, or TCS SP8 confocal microscopes. Some
microscopy images were stitched using the “Stitching” plugin in Fiji (Fig. 1I)
(49) or the Leica LAS X Navigator (SI Appendix, Figs. S2 A and B and S3 B
and C).
Characterization of CCN3 Expression in the CNS.MaleWTmice between 12 and
23 wk of age were perfused with PBS followed by cold 4% PFA between 1300
and 1900 hours. Brains, thoracic spinal cords, and eyes (with attached optic
nerve) were dissected and processed as previously described. Coronal and
sagittal brain frozen sections of 20 μm thickness were cut using a Leica
cryostat. Nonconsecutive coronal sections between 1 mm and −2 mm rela-
tive to bregma were collected, and nonconsecutive sagittal sections of one
hemisphere per brain were collected. Spinal cord (transverse and longitu-
dinal) and eye sections of 12-μm thickness were cut using a Leica cryostat.
After sections were mounted on microscope slides, they were stained
immunohistochemically for various antigens and imaged as described above.
Qualitative assessment of CCN3 expression was performed using at least
five animals.
T Cell Culture. CD4+ T cells were isolated using an EasySep negative selection
kit (19852, Stem Cell Technologies) from splenocytes of male and female,
6–14 wk old, WT mice. Isolated cells consisted of >90% CD4+ T cells. T cells
were activated using plate-bound anti-CD3 (1 μg/mL, clone 145–2C11) and
soluble anti-CD28 (1 μg/mL, clone 37.51) (both eBioscience) for 72 h in Treg-
polarizing conditions: rhTGF-β (4 ng/mL, R&D Systems), rhIL-2 (20 ng/mL,
eBioscience), and anti-IFN-γ (10 μg/mL, clone XMG1.2, Bioxcell). Culture
media consisted of RPMI 1640 (Life Technologies) supplemented with 10%
fetal calf serum (FCS), 1% penicillin/streptomycin, 1% L-glutamine, 1%
Hepes, 1% sodium pyruvate, 1% nonessential amino acids, and 50 nM
β-mercaptoethanol (all Life Technologies). T cells were reactivated in brain
slice medium (described below) for another 72 h, and conditioned media
(CM) were collected. T cell polarization was verified by flow cytometry, and
Treg cultures consisted of >80% Foxp3+ T cells.
CCN3 Quantification and Depletion. Concentration of murine CCN3 in media
from Treg and brain slice cultures was quantified by ELISA (DY1976, R&D
Systems) according to manufacturer instructions. Results were calculated
using linear regression analysis. Values plotted as 0 were below the detection
limit of the kit. CCN3 was depleted from Treg-CM using monoclonal anti-
CCN3 antibody-coupled magnetic beads (clone 231216, R&D Systems and
Thermo Fisher Scientific) or isotype-coupled beads (clone 54447, R&D Sys-
tems). Antibody-bead coupling was performed according to manufacturer’s
instructions. Briefly, 1 mg of beads was incubated with 500 μg/mL antibody.
To immunoprecipitate CCN3, up to 1 mL of Treg-CM was added to 1 mg of
antibody-coupled magnetic beads and incubated for 2 h on a rotator at RT,
vortexing the samples every 15 min. Samples were then placed in a magnetic
stand, and CCN3-depleted Treg-CM and isotype-treated controls were
collected.
OPC Isolation and Culture. Pure OPC (POPC) cultures were generated from
male and female WT P5-9 mice as previously described (45). At day 9 in
culture, PDGFαα and NeuroTrophin 3 (NT3) were withdrawn to allow oli-
godendrocyte differentiation and cells were stimulated with 5% Treg-CM,
5% CCN3-depleted Treg-CM, 5% IgG isotype-depleted Treg-CM, or controls
for up to 3 d. Purity was assessed in random cultures at 3–5 d after setup and
was over 93%.
POPCs were fixed directly in 4% PFA (pH 7.4) (Sigma) for 15 min at RT.
POPCs were blocked in 10% NGS (Vector Laboratories s-1000) with 0.1%
Triton X-100 in PBS for 1 h. Cells were then incubated with primary anti-
bodies for Olig2 (1:400 Millipore AB9610) and MBP (1:1,000 Millipore
MAB386) in 2% NGS with 0.01% Triton X-100 in PBS overnight at 4 °C. Af-
terward, OPCs were incubated with secondary antibodies (1:1,000, goat anti-
rabbit 488, A11034 and 1:1,000, goat anti-rat 594, A11007, both Life Tech-
nologies) for 1 h at RT. Cells were stained with DAPI for 5 min at RT.
Immunofluorescence was detected using an EVOS FL microscope at 10×
magnification and n = 5 wells per condition.
Cerebellar/Brainstem Slice Culture. Cerebellar/brainstem slices (300 μm) from
male and female WT and CCN3−/− P0–2 mice were prepared using a McIlwain
Tissue Chopper and cultured in transwell inserts with brain slice medium
consisting of 46.6% minimum essential medium (Thermo Fisher Scientific),
25% Earle’s balanced salt solution (Sigma), 25% heat inactivated horse se-
rum (HIHS) (Thermo Fisher Scientific), 1% penicillin/streptomycin Thermo
Fisher Scientific), 1% glutamax (Life Technologies) and 1.4% D-(+)-glucose
solution (G8769, Sigma). Slices of WT or CCN3−/− mice were prepared on
separate days and age matched. Slices were allowed to myelinate for up to
14 d. After culture, slices were fixed in 4% PFA for 45 min at RT, washed in
PBS, and blocked/permeabilized for 3 h in solution containing 2% HIHS, 10%
NGS, 1% BSA (Melford Laboratories), and 0.25% Triton X-100 (Sigma). Slices
were stained for MBP (1:600, clone 12, Millipore) and axonal NFH
(1:250–1:400, polyclonal, EnCor Biotechnology) for 2 d overnight at 4 °C.
Slices were then washed three times for 1 h each in 0.01% Triton X-100 in
PBS and incubated with secondary antibodies (1:500, goat anti-rat 568,
AF11077 and 1:500, goat anti-chicken 488, AF11039, both Thermo Fisher
Scientific) overnight at 4 °C. Slices were stained with DAPI for 10 min at RT,
mounted with ProLong Gold Antifade (Life Technologies), and imaged with
a Leica TCS SP8 confocal microscope at 0.5-μm intervals. The whole slice
thickness was imaged. Three fields of view (FOV) were imaged per slice, and
three slices were imaged in this manner per animal (total of nine FOV per
animal were analyzed to generate one mean value per animal for statistical
analysis). An ImageJ macro (34) was used to determine the myelination in-
dex (MBP+NFH+ colocalization area/NFH+ total area). Only images within the
z-stack with uniform NFH staining were included in the analyses. To quantify
the number of CCN3+ cells in cerebellar/brainstem slices, slices were stained
for CCN3, NFH, and NeuN with primary antibody concentrations indicated in
SI Appendix, Table S1 and a 1:500 dilution factor for corresponding sec-
ondary antibodies. One focal plane overview of every slice was imaged using
Leica LAS X Navigator software and a TCS SP8 confocal microscope. The
number of cells were then counted using Fiji software. A total of three slices
were imaged in this manner per animal to generate one mean value per
animal for statistical analysis.
Statistical Analyses. No statistical methods were used for sample size de-
termination; sample sizes are similar to those reported in similar studies (9, 42,
50). Datasets comprising two groups for comparison were tested for normal
distribution and statistical significance using unpaired two-tailed Student’s
t tests for parametric data, or Mann–Whitney U tests for nonparametric
data, as detailed in figure legends. Datasets comprising more than two
groups for comparison were tested for normal distribution and statistical
significance using one-way ANOVA with Bonferroni’s multiple comparison
test for parametric data, or Kruskal–Wallis with Dunn’s Multiple Comparison
test for nonparametric data, as detailed in figure legends. Normality of
datasets was tested using the Kolmogorov–Smirnov, Shapiro–Wilk, and
D’Agostino Pearson normality test methods. Statistical analyses of percent-
age data were performed using nonparametric tests. Statistical analyses and
graphing of data were performed using GraphPad Prism 8.
Data Availability Statement.All data discussed in the paper are available in the
main text or SI Appendix.
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